It has been proven that an inhibitor targeted at HIF1 such as digoxin can block BC progression (Zhang et al., 2012) and enhance paclitaxel or gemcitabine chemosensitivity by regressing breast cancer stem cell (BCSC) enrichment (Samanta et al., 2014). This evidence concerns the gene HIF1A and breast cancer.